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Abstract
After remarkable success of vector control campaigns worldwide, concerns about loss of immunity against Plasmodium
falciparum due to lack of exposure to the parasite are relevant since an increase of severe cases in less immune individuals is
expected. We present a mathematical model to investigate the impact of reducing exposure to the parasite on the immune
repertoire against P. falciparum erythrocyte membrane protein 1 (PfEMP1) variants. The model was parameterized with data
from Prı´ncipe Island, West Africa, and applied to simulate two alternative transmission scenarios: one where control
measures are continued to eventually drive the system to elimination; and another where the effort is interrupted after 6
years of its initiation and the system returns to the initial transmission potential. Population dynamics of parasite prevalence
predict that in a few years infection levels return to the pre-control values, while the re-acquisition of the immune repertoire
against PfEMP1 is slower, creating a window for increased severity. The model illustrates the consequences of loss of
immune repertoire against PfEMP1 in a given setting and can be applied to other regions where similar data may be
available.
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Introduction
Remarkable success of malaria control campaigns has been
achieved in the last decade, with a 25% decrease in worldwide
deaths [1]. Many of the control campaigns rely on vector control
interventions that have been especially effective in reducing the
transmission of Plasmodium falciparum, the most deadly human
malaria parasite [2–3]. Transmission reduction comes with the
side effect of promoting loss of naturally acquired immunity
against parasite antigens that are important in controlling the
progression of the parasite life cycle in the host and preventing
complicated disease outcomes [4]. With many obstacles arising for
P. falciparum elimination, such as insecticide and drug resistance,
high genetic diversity and breakdown of control campaigns [5–7],
transmission might re-emerge, with infections causing more severe
disease due to declining immunity levels [4].
The P. falciparum erythrocyte membrane protein 1 (PfEMP1)
family is very important both for the pathogenesis of falciparum
malaria and for naturally acquired immunity to the disease [8].
This protein is responsible for the cytoadherence of infected
erythrocytes to vascular endothelial receptors and plays an
important role in malaria pathogenesis by modifying the
microcirculation and allowing parasites to escape clearance by
the spleen [9]. PfEMP1 is a variable surface antigen (VSA) of P.
falciparum and is a major factor of immune evasion by the parasite
since it has the ability of switching expression amongst different
variants, a process known as antigenic switching [10]. The
presentation of variants to the host is hierarchical, in the sense
that dominant variants are more cytoadherent and more likely to
cause severe disease, being predominantly expressed in naı¨ve
hosts. As hosts acquire immunity, less dominant variants are
expressed [11–13]. Due to the considerable intraclonal and
interclonal variability of genes encoding for this protein (var genes,
about 60 per haploid genome and with fast recombination) [14],
immunity against PfEMP1 is practically never fully acquired.
However, individuals from endemic areas are able to maintain a
broad antibody repertoire due to persistent exposure to the
parasite [15]. Upon reducing transmission, there is concern that
waning serological immunity to PfEMP1 antigenic variants may
render individuals more vulnerable to disease.
Mathematical modeling is a useful tool in the assessment of
transmission scenarios and control measures [16]. It has also been
used to relate transmission with measures of serological markers
[17], to simulate the dynamics of within-host acquisition of
PfEMP1 variants and its impact on the life cycle of the parasite
[18–20], and to study evolutionary mechanisms acting on var genes
at the population level [12;21]. In this work, we link transmission
scenarios in a setting undergoing control measures towards
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elimination with the breadth of the immune repertoire against
PfEMP1. The dataset used was collected in Prı´ncipe Island, the
smallest island of Sa˜o Tome´ and Prı´ncipe, an archipelago in West
Africa. Prı´ncipe has been classified as a meso/ hyperendemic
malaria region with perennial transmission in most areas. Since
2004, control measures have been very successful, with the island
having low and stable transmission since 2007 [22]. However,
measures of transmission and identification of malaria carriers
were mainly based on optical microscopy diagnostics. We use,
along with serological data for a subset of intraclonal variability of
PfEMP1, infection data obtained by polymerase chain reaction
(PCR), a technique that detects more efficiently the asymptomatic
cases that constitute a reservoir for transmission [23].
Materials and Methods
Informed consent and ethical permits
Ethical permit to conduct this study was granted by the Ministry
of Health of S. Tome´ and Prı´ncipe in the scope of a collaborative
protocol between the Fundac¸a˜o Calouste Gulbenkian and the S.
Tome´ e Prı´ncipe government on Malaria research. Written
informed consent was obtained from every participant. In case
of children participants, written consent was obtained from the
guardians.
Sample collection
In 2005 a population-based study was conducted, covering most
villages in the Prı´ncipe Island. Blood samples were collected from
apparently healthy participants without any prior selection or
restrictions on participation. The age distribution of the sampled
individuals ranged from 1 month to 85 years of age. For each
participant, a malaria clinical and epidemiological enquiry was
filled in.
Malaria carrier detection
To detect parasite DNA in peripheral blood, DNA was
extracted using 96 Qiamp Blood kit. A nested PCR amplification
assay was used for the detection of the main four human malaria
species as described in [24].
Anti-parasite antibodies
The anti-var antibody profiling technique has been used to
identify naturally acquired immunity to P. falciparum [13] and can
be summarized as follows: Forty-five recombinant proteins
representing domains present in different PfEMP1s from the
3D7 clone were expressed. The domains were chosen to represent
PfEMP1s belonging to different groupings (groups A, B/A, B or C)
comprising domains of different types and located in different
regions of the proteins. For a more detailed description of the
tested variants see Table S1. Carboxylated luminex microspheres
were covalently coupled with the different PfEMP1 domains
according to the manufacturer’s protocol. Each protein was
coupled to a particular fluorescence-coded microsphere type. To
determine domain-specific IgG levels in the plasma, lyophilized
microspheres were reconstituted immediately prior to use. Frozen
plasma samples were thawed at room temperature, diluted by 1:80
in ABE buffer and 50 ml aliquots were added to the microsphere
wells. After incubation, Biotinylated anti-human IgG antibody was
added to the microspheres. This was followed by streptavidin-
phycoerythrin. Finally, the microspheres were re-suspended in and
analyzed on a Luminex 100 IS instrument set to read a minimum
of 100 microspheres per microsphere region. Antibody levels for
each domain were expressed as median fluorescent intensity
(MFI). We used a seronegativity cut-off value based on the
reactivity measured in plasma from unexposed control donors.
Data processing and management
All data were double entered and checked in Microsoft Excel
spreadsheets. Initial conditions for the simulations were estimated
from the 2005 survey data. Individuals with incomplete fields such
as age and parasitemia, as well as with insufficient serum for
serological analysis, were not considered for further analysis. After
these adjustments, 535 samples with age, parasitological and
serological information were obtained. To avoid possible immu-
nity confounders from infections with other Plasmodium parasites, a
subset with only uninfected and P. falciparum infected individuals
(including mixed infections) was obtained, consisting of 517
individuals. To remove the effect of possible maternally-acquired
immunity, individuals aged less than 1 year at the time of the
survey were removed from the analysis. For each individual, the
number of acquired antibody specificities and variants was
calculated. To test whether the acquisition of antibodies for
different epitopes of the same PfEMP1 variant is related, where
applicable, Spearman’s correlation test was applied.
Models of infection and immunity dynamics
For the infection dynamics, we adopted a susceptible-infected-
susceptible (SIS) framework derived from the basic model of Ross
[25]. The model is formulated as a system of partial differential
equations on age and time [26], and the endemic equilibrium that
this describes was fitted to the prevalence data. The data was
organized by structuring the 2005 sample population into 9 age
groups and, initially, two model parameters were estimated: the
transmission coefficient (b) and the clearance rate (c). It was
assumed that, before the 2005 survey, the population was in
endemic equilibrium to allow parameter estimation using the age
prevalence data from the initial survey. Demography was included
in the model by a birth and death rate (m) considered as the inverse
of the mean life expectancy in Sa˜o Tome´ and Prı´ncipe in 2005
(63.9 years) [27]. For the proposed model, the basic reproduction
number (R0) is approximately the ratio of the transmission
coefficient by the clearance rate, and we opted to estimate b
and R0 in the first instance, and from these calculate c. This
approach minimized correlation between the parameters and
improved confidence on the estimates. To obtain parameter
estimates using a Bayesian framework, Markov Chain Monte
Carlo (MCMC) methods were implemented using the Metropolis-
Hastings algorithm. The priors for the two parameters were
uniformly distributed, ranging from -5 to 3 in loge scale. The
model likelihood is based on the binomial distribution of the
proportion of infected individuals. Two chains were run in parallel
starting from overdispersed initial values to ensure convergence of
the chain irrespectively of the starting value. The chains were run
for 45,000 iterations, with a burn-in period of 100 iterations and a
thinning factor of 45, resulting in 1000 posterior samples for
parameter inference. Stationarity of each chain was assessed using
the Heidelberg and Welch test and convergence of the over-
dispersed chains to the same stationary distribution was confirmed
by applying the Gelman-Rubin diagnostic. Time simulations of
the population-wide infected proportions were run by implement-
ing an intervention that decreases the transmission coefficient to
one half. Scenarios were projected by simulating the model until
2024, under two alternative assumptions regarding the transmis-
sion coefficient: (i) remaining at the reduced level achieved by the
intervention; (ii) returning to the original level 6 years after the
start of the intervention.
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Acquisition and loss of antibodies against PfEMP1 variants
expressed by specific var genes was modeled through a counting
process of the number of PfEMP1 variants an individual has
acquired immunity to. The framework hereby presented extends
reverse catalytic models used to study seroconversion and
seroreversion to a given antigen [17] by applying queuing theory
as in previous formulations of superinfection [28]. Detection of
antibodies was focused on a set of 26 variants, thus a system of 27
partial differential equations was developed to describe the
dynamics of acquisition and loss of immunity against PfEMP1
variants. Each state describes the number of variants a person has
immunity to. Seropositivity was described as having a mean
fluorescent intensity (MFI) above a cut-off value obtained from a
cohort of naı¨ve individuals (see data description). Preserving the
aforementioned assumption of endemic equilibrium, the param-
eters of the model, seroconversion (l) and seroreversion (r) rates,
were estimated based on the 2005 data by grouping the 27
compartments into 3 categories: seronegative individuals; individ-
uals with immunity to 1–10 variants; and individuals with
immunity to 11 or more variants. Initially, the model represented
acquisition of immunity in unitary steps (i.e. one variant per
infection event) at rates independent of the prior number of
variants. In order to take into account the possibility of an infected
individual being exposed to more than one variant during a single
infection due to the process of antigenic switching, the model was
extended to allow for the acquisition of immunity to more than
one variant during a single infection. To the number of variants
acquired in the course of a given infection we call the
seroconversion step. The seroconversion step is assumed to
decrease linearly with the number of variants recognized by the
immune system prior to each specific infection. Figure 1 illustrates
how this decrease is approximated by a step function since only
integer values are permissible.
Regarding the loss of antibodies, the rate of seroreversion is the
same for all the states and independent for each variant. Since the
factors that modulate seroconversion in each state are fixed, two
parameters remain to be estimated (l and r). Models with different
initial seroconversion steps were compared with the unitary step
model by comparing the Akaike Information Criterion corrected
for small sample size (AICc). The model with the minimum value
of AICc is considered the best fitting model and will be used for
time simulations. For parameter estimation of the seroconversion
rate and the seroreversion/seroconversion ratio for each model, to
avoid correlation issues, MCMC chains were run in a similar
manner as described for the transmission model. Uniform priors
were used for both parameters and the likelihood had a
multinomial distribution. Chains were run for 160,000 iterations
with a burn-in period of 2000 iterations and 1000 iterates kept for
parameter inference. The applied convergence tests were the same
as for the transmission model and 95% credible intervals were
calculated. Time simulations of the PfEMP1 immune repertoires
were performed through the vector control campaign by applying
to a seroconversion reduction factor calculated from the imposed
reduction in the transmission coefficient.
Model equations
1) SIS model. The partial differential equation (PDE) system
in age and time domains that was used to model transmission is
written as follows:
LS
Lt
z
LS
La
~{b(t) I S{m Szc I
LI
L t
z
LI
La
~b(t) I S{ czmð Þ I ,
ð1Þ
where b(t) is implemented in a stepwise manner to mimic the
intervention:
b(t)~
b0
b0
2
b0
8><
>:
if t~0
if 0vtvtc
if t§tc
: ð2Þ
In (2), tc represents the time of intervention breakdown, here
considered as tc~6 years. The case where the intervention is
maintained indefinitely is formalized as tc??. The per capita rate
of infection (force of infection) is L(t)~b(t) I(t), and the boundary
conditions for the system at age a = 0 are:
S(t,0)~m
I(t,0)~0:
ð3Þ
For ease of visual representation of the obtained results and
fitting, the proportions were normalized with respect to the
approximated distribution of population over age
P(a)~m e{m a, ð4Þ
with the fittings being performed using the normalized differential
equations and adjusting to the proportions of infected individuals
in each age group.
Figure 1. Seroconversion step with respect to the number of
PfEMP1 variants in the immune repertoire prior to infection.
Dark gray: Situation with no antigenic switching implied, acquisition of
one variant per infection event. Light gray: Situation with antigenic
switching, with the number of variants acquired per infection varying
with the number of variants the individual has prior to infection.
Example assuming a seroconversion step of 6 variants in a completely
seronegative individual.
doi:10.1371/journal.pone.0088110.g001
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The non-trivial equilibrium solution for the infected compart-
ment of the system in (1) is:
I~1{
mzc
b
ð5Þ
.
From (5), we derive the basic reproduction number, R0, as:
R0~
b
czm
ð6Þ
.
2) PfEMP1 immunity model. First we describe the model
for acquisition of one PfEMP1 variant per event and then extend it
to accommodate the acquisition of immunity to multiple variants.
Let Pi represent the state ‘‘seropositive to i variants’’. Therefore,
P0 represents the seronegative individuals, that is, those who have
not been exposed to the parasite or have lost immunity to the set of
variants previously acquired. At the other end, Pn represents the
individuals that have been exposed and retain immunity to all the
n variants considered in this representative set (n~26 as previously
mentioned). The model is represented as follows:
LP0
Lt
z
LP0
La
~{ l(t)zmð ÞP0zrP1
LPi
Lt
z
LPi
La
~l(t)Pi{1{ l(t)zrzmð ÞPizrPiz1, for i[ 1, . . . ,n{1f g,
LPn
Lt
z
LPn
La
~l(t)Pn{1{ rzmð ÞPn
ð7Þ
with boundary conditions at age a = 0, assuming no
maternally-acquired immunity, given by:
P0(t,0)~m
Pi(t,0)~0, i[ 1, . . . ,nf g:
ð8Þ
The fitting procedure also involved the calibration of the
normalized differential equation values in the age domain with the
proportions of individuals in each of the three categories defined for
estimation, specifically: 0 variants; 1–10 variants; more than 11
variants. The seroconversion rates vary over time proportionally with
the variation of the force of infection estimated by the SIS model:
l(t)~l(0)
L(t)
L(0)
ð9Þ
.
For the model concerning a seroconversion step that decreases
with the number of variants in the immune repertoire prior to
infection, we developed a stepwise framework that approximates a
linear dependence. Consider the seroconversion step when an
infection occurs in an individual on the state Pi to be given by:
s(i)~q{ n0n
 
izn0r ð10Þ
where n0 represents the seroconversion step in completely
seronegative persons, that is, when i = 0. To know the final
state, w, after an event of seroconversion we sum the initial state to
the seroconversion step:
w~f (i), where f (i)~izs(i) ð11Þ
Seroconversion events are then represented as transitions from
initial states Pi to final states Pw with rates determined by the basic
rule just described. Seroreversions are more simply implemented
as transition from Pi to Pi{1 at fixed rates for all individuals
regardless of their age/immune status.
According to the described seroconversion mechanism, the set
of indices, i, that lead to a given final state, w, may contain zero,
one or two elements as given by the inverse operation i~f{1(w).
The full system is then represented by the following set of
equations:
LP0
L t
z
LP0
La
~{ l(t)zmð ÞP0zrP1
LPw
L t
z
LPw
La
~l(t)
X
i[f{1(w)
Pi{ l(t)zrzmð ÞPwzrPwz1, for w[ 1, . . . ,n{1f g,
LPn
L t
z
LPn
La
~l(t)
X
i[f{1(w)
Pi{ rzmð ÞPn
ð12Þ
while an expanded representation for the specific scenario n~26 and initial
seroconversion step of 6 (illustrated in Figure 1) is provided in Text
S1.
The mean number of antibodies at age a is calculated from the
estimated Pi’s. Finally, the seroconversion step, which we have so
far represented in terms of the number of variants prior to
infection, can also be represented in terms of age at infection by
calculating the mean number of antibodies by age, i(a), and
applying the following transformation:
s(a)~q{ n0n
 
i(a)zn0r ð13Þ
Model implementation and parameter estimation
For parameter estimation purposes, equilibrium in time was
assumed and the resulting models were implemented as ordinary
differential equations (ODEs) in the age domain and solved
numerically using the ‘‘deSolve’’ package of R v2.14.1. To select
the best-fitting models for the PfEMP1 variant dynamics,
maximum likelihood estimates based on a multinomial error
distribution were performed and compared using AICc with
functions from the ‘‘bbmle’’ package in R. MCMC parameter
estimation procedures were also implemented in R and evaluated
with several diagnostic procedures through functions of the
packages ‘‘MCMCpack’’ and ‘‘coda’’. For time simulations, the
system of PDEs was implemented and solved in MATLAB
R2011a using the ‘‘pdepe’’ routine, considering the solutions of the
age-dependent ODEs for each age as the initial conditions for time
simulation.
(7)
(12)
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Results
Parasite surveys
Using the 535 samples of the serological and parasitological
survey in 2005, the total prevalence of malaria infections is
30.28% (162/535). The relative percentage of infections is shown
in Table 1. When subsetting to a group with only P. falciparum
infections (including mixed infections) and uninfected individuals,
the prevalence of P. falciparum infections is 27.85% (144/517).
Relationship between antibodies for the same PfEMP1
variant
Out of the 26 recombinant PfEMP1 in the dataset, 11 had more
than one epitope represented. In order to know if an increase in
the levels of one epitope led to an increase in the levels of other
epitopes of the same variants, Spearman’s correlation was
computed for these variants. For 8 of the 11 variants, the
Spearman correlation coefficient was above 0.7, indicating a high
positive correlation between the levels of antibodies for epitopes of
the same variant. All the responses were positively correlated,
confirming that acquisition of antibodies for epitopes of the same
variant is not independent and laying the foundation for a model
based on recognition of variants instead of presence of antibodies
against individual epitopes.
Transmission model and simulations
Due to high correlation of the estimates for parameters b and c
of the SIS model (1), we opted to estimate b and R0 and calculated
the value of c using the equilibrium derivation in (5) and (6). The
estimated values for b and R0, as well as for the dependent
parameters c and L, and the 95% credible intervals, are present in
Table 2. The best fitting model simulation with respect to the
original infection data is shown in Figure 2, as well as time
projections for the following 2.5 and 5 years, assuming an
intervention where the transmission coefficient b is reduced to one
half of the initial value.
The distribution of b is skewed to low positive values but the
credible intervals are broad due to the presence of outliers. These
outliers may be related to heterogeneous exposure, particularly
focal areas of high exposure. Due to the high correlation of b and
c, the high variability in the estimates does not translate into a high
variability of the basic reproduction number (R0), estimated to be
slightly above 1, as of 2005. The estimated clearance rate c in 2005
is 2.3280 year21 according to the mean statistic (duration of
infection of about 5 months) and 0.8695 year21 according to the
median (duration of infection of about 1 year). These values are
compatible with estimates obtained by fitting a panel of refined
models to data from more than 90 communities [29]. Moreover,
the broad credible intervals accommodate scenarios of faster
clearance in the case of clinical infections undergoing treatment, as
suggested by previously models [30–31].
Using the median values for the obtained estimates, since these
are more robust measures of the characteristics of the population,
we performed time simulations of the proportion of infected
individuals. Simulations were implemented by inducing a decrease
in the transmission coefficient to one half beginning in 2005. After
this initial period two scenarios were simulated: one where the
intervention effort continues indefinitely; and another where the
intervention is halted in 2011 (6 years after its start) and the
transmission potential returns to the original level. The values of
the transmission coefficient and the simulated prevalence results
are shown in Figure 3.
With the reduced transmission coefficient, the proportion of
infected individuals will decrease gradually and, therefore, the
force of infection will decrease as well. If the simulated control
measures were kept with the same effort indefinitely, the level of
infected individuals would decrease to very low values (circa 1% of
Table 1. Global prevalence of infection in 2005 in Prı´ncipe
Island and relative prevalence of each type of infection.
Infection type Prevalence Relative prevalence
P. falciparum 23.93% (128/535) 79.01% (128/162)
P. vivax 1.31% (7/535) 4.32% (7/162)
P. ovale 0.75% (4/535) 2.47% (4/162)
P. malariae 1.12% (6/535) 3.70% (6/162)
Mixed 3.18% (17/535) 10.49% (17/162)
doi:10.1371/journal.pone.0088110.t001
Figure 2. Infection data by age in 2005, SIS model (1) fit and
projected intervention impacts. True proportions per age group
are represented by black circles. Black curve: SIS model with the best fit
parameters in 2005. Dark gray curve: Prediction of the infected
proportions by age in 2008 (2.5 years after the beginning of the
intervention). Light gray curve: Prediction of the infected proportions
by age in 2010 (5 years after the beginning of the intervention).
doi:10.1371/journal.pone.0088110.g002
Table 2. Mean and median values with 95% credible intervals
for the distributions of estimated parameters for the SIS
model (1).
Parameter Mean estimate Median estimate 95% CI
b 3.249 1.236 0.3553–16.606
c 2.3280 0.8695 0.2339–11.8092
R0 1.424 1.419 1.3327–1.537
L 0.9211 0.3627 0.1170–4.5552
doi:10.1371/journal.pone.0088110.t002
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infected individuals) after 20 years, eliciting good prospects for
elimination. After only 5 years of effective intervention measures
(Figures 2 and 3B), the prevalence of infection would fall below
5%, being very low for every age group. However, if control
measures are interrupted and the transmission coefficient returns
to the pre-intervention value, within a decade after the interven-
tion breakdown the population levels of infected individuals return
to levels near the initial proportion of c.a. 28%. In this simulation
there is no distinction between clinical and asymptomatic, or
between infectious and non-infectious cases, but it is plausible that
loss of population immunity due to reduced exposure to the
parasite could result in increased severity and infectivity in case of
re-emergence.
PfEMP1 immunity model and simulations
The results of the fittings by maximum likelihood methods using
a multinomial error for the immunity model (13) with different
seroconversion steps are shown in Table 3, as well as the respective
AICc values.
Using this criterion, it is clear that the best fit, corresponding to
the smaller value of AICc, is provided by the model with an initial
seroconversion step of 6 var genes. The parameter estimation
results for the model with initial seroconversion step of 6 variants,
as well as the respective 95% credible intervals, is shown in Table
4. Graphical representation of the best fitting model against
proportions of individuals in each of the antibody repertoire
categories can be seen in Figure 4. The mean number of antibody
variants and seroconversion steps by age are shown in Figure 5.
The impact of transmission changes on the broadness of the
immune repertoire of the individuals in the population is shown in
Figure 6. The simulations were performed using the same
transmission coefficient factors to modulate both infection and
seroconversion rates, according to expression (9).
Under the model where up to 6 variants are acquired in a single
infection, the loss of antibodies when transmission decreases is
considerable within 5 years of intervention, with a considerable
proportion of the population being immunologically naı¨ve due to
lack of exposure (Figure 5A and 6). This may lead to considerable
risk of severe disease in the years after transmission re-emergence,
mostly evident in older individuals in highly endemic settings. The
potential for seroconversion given a new infection (Figure 5B)
increases to the expected value for naı¨ve individuals and, although
this facilitates the re-establishment of immunity, the pace of
immunity recovery remains slower than that of infection rebound
Figure 3. Implementation of transmission changes and associ-
ated infected dynamics. A: Black: Simulation of an intervention that
reduces the transmission coefficient to one half of the pre-intervention
equilibrium value. Gray: The same intervention but with relapse to the
pre-intervention value in 2011 (6 years after the intervention started). B:
Curves generated by model (1). Black: Infected proportions over time
when the transmission coefficient is reduced to one half, indefinitely.
Gray: Infected proportions over time when the transmission coefficient
is reduced to one half, returning to the initial value in 2011.
doi:10.1371/journal.pone.0088110.g003
Table 3. Comparison between implementations of the
PfEMP1 model (13) with different seroconversion steps.
Initial step
(nvars) L R AICc
1 14.2684 14.3189 142.5053
2 2.7416 4.5700 133.6528
3 1.5154 3.3920 121.1597
4 1.0570 2.9597 109.3547
5 0.7656 2.6473 99.1733
6 0.6347 2.5230 97.1156
7 0.5300 2.4491 98.4256
8 0.4863 2.5446 104.1059
9 0.4596 2.6981 111.6555
10 0.4313 2.7984 120.1354
11 0.4164 3.0210 138.1856
12 0.4387 3.5201 157.8700
13 0.4846 4.1849 175.283
Evaluation of the best initial step is performed by computing the Akaike
Information Criterion with small sample size correction (AICc).
doi:10.1371/journal.pone.0088110.t003
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(compare Figures 3B and 6). In fact, the mean number of variants
in the population does not return to the pre-intervention values
within twenty years of pre-intervention levels of transmission while
infection does.
The unitary seroconversion step model (7) predicts a faster
decay of immunity and even slower recovery upon transmission
rebound. For comparison we refer to supporting information,
where Table S2 can be contrasted with Table 4, and Figures S1–
S3 with Figures 4, 5, 6, respectively. Although the 2005 data
presented here gives better support for the model where up to 6
variants are acquired in a single infection it would be interesting to
confront these predictions with follow-up data from the island.
Discussion
We have parameterized infection and immunity models to
represent the endemic state of P. falciparum malaria in the Prı´ncipe
Island in 2005, and simulated intervention scenarios. One of the
strengths of this study is the availability of a detailed dataset
relating PfEMP1 antibody repertoires with host age and parasite
prevalence. As interventions to reduce transmission in the island
have started to gain significance just after the collection of this
data, our study reports a unique pre-intervention analysis essential
for future intervention assessment. Simulations are consistent with
the qualitative expectations that reduced transmission will result in
decrease of exposure, narrowing the immune repertoire at the
Figure 4. PfEMP1 model (13) with initial seroconversion step of 6 variants and age data in 2005. True proportions per age group are
represented by black circles. Gray curves: Estimated proportions by age for each category. Top: Individuals with no immunity. Middle: Individuals with
immunity to 1–10 variants. Bottom: Individuals with immunity to more than 11 variants.
doi:10.1371/journal.pone.0088110.g004
Table 4. Parameter estimates for the PfEMP1 model (13) with
state-dependent seroconversion step and initial step of 6
variants.
Parameter Mean estimate Median estimate 95% CI
l 0.6468 0.6394 0.4988–0.8350
r 2.5799 2.5500 1.9250–3.4170
doi:10.1371/journal.pone.0088110.t004
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population level and reducing disease protection. More quantita-
tive descriptions can be generated by adjusting these models to
similar data collected post-intervention, as well as to provide a
more accurate parameterization of the evolution of infections and
immune repertoire over time. There is a crucial role for
mathematical modeling in balancing the benefits of reducing
transmission with the costs of increasing susceptibility.
Two major concerns in malaria control are the severity of
disease in infected individuals and their infectivity to mosquito
vectors. In the absence of data on severity of infections and
gametocyte counts, we have not specified these variables in the
model, since the main goal was to simulate the dynamics of the
PfEMP1 immune repertoire. However, the described results are
likely to have implications on the patterns of disease severity and
infectivity.
This model has not incorporated any degree of heterogeneity in
host susceptibility, in the exposure to the parasite and the degree of
treatment with antimalarials. It is known that individuals with
certain genetic traits, apart from the sickle-cell trait, are less
susceptible to develop blood-stage parasitemia [32–33]. Previously
reported mathematical models of malaria have incorporated
heterogeneities in exposure by including age-dependence [34],
groups of high and low susceptibility/exposure [29], distributions
of the duration of infection [35] and the effect of antimalarials
[36–38]. Not incorporating these effects in the transmission
models may compromise the accuracy of parameter estimates,
and there is always room for model refinement. However, in the
current study there was no need, when fitting the data, to
incorporate age-dependent force of infection and clearance rates
(age was not a significant factor associated with parasitemia in
2005 as assessed by the Kruskall-Wallis test, p = 0.36), in
coherence with a recent study [39].
Figure 5. Equilibrium antibody repertoires and seroconversion steps by age with initial step of 6 variants. A: Mean number of PfEMP1
variants by age. Black circles: true means per age group in 2005. Black curve: model (13) fit to 2005 data. Dark gray: projection for 2008 (2.5 years after
the beginning of the intervention). Light gray: projection for 2010 (5 years after the beginning of the intervention). B: Seroconversion step by age.
Black curve: 2005, from the best-fit model. Dark gray: 2008, projected. Light gray: 2010, projected.
doi:10.1371/journal.pone.0088110.g005
Figure 6. PfEMP1 variants averaged over the population
assuming initial seroconversion step of 6 variants. Curves
generated by model (13). Black: transmission coefficient is reduced to
half of its initial value, until the end of the simulation. Gray: transmission
coefficient is reduced to half of its initial value, and relapses back to the
initial value in 2011 (6 years after the intervention started).
doi:10.1371/journal.pone.0088110.g006
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Focusing on the dynamics of PfEMP1 immunity, apart from the
fact that multiple events of exposure to the parasite are required to
seroconvert to a given antigen, the fact that seroconversion to
several variants per event was a more appropriate description to
the given immunity is in agreement with previous models [18;40].
Despite the fact that the data available from the 2005 survey gives
better support for the model where up to 6 variants are acquired in
a single infection, it would be interesting to confront these
predictions with follow-up data from the island. More mechanistic
descriptions would require understanding of the intervals between
parasitemia peaks in the field and the relative dominance of
variants and acquisition of immunity to non-dominant variants.
The incorporation of these factors may help to better understand
the relationship between antigenic switching, intra-host competi-
tion and the possibility of acquisition of immunity to several
variants per event.
It is also important to state that only intraclonal variability is
being considered here, since almost all the recombinant proteins
used for antibody detection were obtained from the 3D7 strain of
P. falciparum. This strain is from unknown origin and might not be
circulating anymore in the field [13;41]. Furthermore, the
possibility of detecting antibodies against the listed recombinant
proteins relies on the possibility of cross-reactivity of the antibodies
of the individuals against domains of proteins of different clones or
the degree of similarity between the variants expressed in the field
and the ones expressed by the 3D7 isolate [42]. Another approach
that would give a more informative view of the immunity against
the strains present in the field would be a prior population genetics
characterization of the P. falciparum strains in circulation and a
measure of antibody responses against proteins they express. This
approach has been used with success for characterization of
antibody responses against PfEMP1 domains [41] and would allow
to better characterize evolution and diversity of var genes in nature.
In this work, to define seropositivity we used a cut-off from
responses of non-immune individuals, in agreement with previous
models for seroconversion to a single antigen [17]. The use of a
cut-off defined in this fashion is arbitrary and its use excludes the
information about the magnitude of the immune response of each
individual. The use of stochastic modeling would provide a more
convenient framework to include individual variability on the
levels of antibodies against each variant. With this information, it
would be possible to characterize the variants in terms of
immunogenicity and possibly to infer which variants are more
commonly presented to the host immune system. As implemented
here, the simulations refer to a counting process and do not
consider which variants are present through time. Since there is
evolution of the var genes under several factors including immune
pressure and the composition of the susceptible pool in the
population [43], despite the fact that the number of acquired
variants in a person may be the same before the intervention and
after a re-emergence, the risk of disease may not be the same
because the variants may have changed. For a more detailed
description of the framework of evolution and immune selective
pressure on the var genes at the population level, a longitudinal
framework for data acquisition would be more appropriate in
order to know the immune and infectious history of the
individuals.
Shortly, based on malaria epidemiology in a West African
island, we have developed mathematical models to characterize
and simulate infection and immunity scenarios for variant surface
antigens of P. falciparum. These models and the proposed
extensions may be applied to other settings and guide health
policies by predicting the impact of current and prospective efforts
for malaria elimination.
Supporting Information
Figure S1 PfEMP1 model (7) with unitary seroconversion step
and age data in 2005. True proportions per age group are
represented by black circles. Gray curves: Estimated proportions
by age for each category. Top: Individuals with no immunity.
Middle: Individuals with immunity to 1–10 variants. Bottom:
Individuals with immunity to more than 11 variants.
(TIF)
Figure S2 Equilibrium antibody repertoires assuming unitary
seroconversion step. Mean number of PfEMP1 variants by age.
Black circles: true means per age group in 2005. Black curve:
model (7) fit to 2005 data. Dark gray: projection for 2008 (2.5
years after the beginning of the intervention). Light gray:
projection for 2010 (5 years after the beginning of the
intervention).
(TIF)
Figure S3 PfEMP1 variants averaged over the population
assuming unitary seroconversion step. Curves generated by model
(7). Black: transmission coefficient is reduced to half of its initial
value, until the end of the simulation. Gray: transmission
coefficient is reduced to half of its initial value, and relapses back
to the initial value in 2011 (6 years after the intervention started).
(TIF)
Table S1 PfEMP1 variants and epitopes evaluated in this study.
(PDF)
Table S2 Parameter estimates for the PfEMP1 model (7) with
unitary seroconversion step and 95% credible intervals.
(PDF)
Text S1 PfEMP1 model with 26 variants (n = 26) and initial
seroconversion step of 6 variants (n0 = 6).
(PDF)
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